Andrew Baum
Stock Analyst at Citigroup
(2.85)
# 1,621
Out of 4,829 analysts
62
Total ratings
69.77%
Success rate
12.23%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $75.97 | +51.38% | 13 | Feb 5, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $22.28 | +30.16% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $46.45 | +39.94% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $33.15 | +20.66% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $184.60 | +16.47% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $734.57 | +21.84% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $9.63 | +3.84% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $36.62 | - | 2 | Jul 5, 2017 |
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $75.97
Upside: +51.38%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $22.28
Upside: +30.16%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $46.45
Upside: +39.94%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $33.15
Upside: +20.66%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $184.60
Upside: +16.47%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $734.57
Upside: +21.84%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $9.63
Upside: +3.84%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $36.62
Upside: -